ClinicalTrials.gg
CompletedNCT01297595Updated Feb 16, 2012Results posted

Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule

A Phase 1 interventional study of crizotinib in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-16.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will be an open-label, randomized, 2-period, 2-treatment, 2-sequence, cross-over single-dose study employing administration of two oral formulations of crizotinib (OLF and FC) in the fasted state to healthy adult subjects. Twenty-two (22) subjects will be enrolled to obtain at least 20 evaluable subjects who complete the study. Each subject will receive two treatments (A and B) with a washout period of at least 14 days between each treatment.

02

Conditions studied

  • Healthy

Keywords

  • relative bioavailability
  • pharmacokinetics
  • crizotinib
  • oral liquid formulation
  • formulated capsule
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. Healthy is defined as no abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead or clinical laboratory tests.
  • (BMI) of 17.5 to 30.5 kg/m\^2; and a total body weight >50 kg (110 lbs).

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Any condition possibly affecting drug absorption (eg, gastrectomy).
  • A positive urine drug screen.
  • History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
  • Treatment with an drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
  • 12-lead demonstrating >450 msec or a QRS interval >120 msec at screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTc or QRS values should be used to determine the subject's eligibility.
  • Pregnant or nursing females; females of , including those with tubal ligation.
  • Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal supplements and hormonal replacement therapy must be discontinued 28 days prior to the first dose of study medication. As an exception, acetaminophen/paracetamol may be used at doses of ≤1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.
  • Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • Unwilling or unable to comply with the Lifestyle Guidelines described in this protocol.
  • Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  • A positive serology for or .
  • Subjects who currently smoke.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    crizotinib

    Drug: crizotinib

Interventions

  • Each subject will receive 250 mg single oral doses of oral liquid formulation and formulated capsule of crizotinib separated by at least 14 days.

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Infinite Time [AUC (0 - ∞)]

    AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hours (hrs) post crizotinib dose

Secondary outcomes

  1. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose

  2. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose

  3. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose

  4. Plasma Terminal Half-Life (t1/2)

    Plasma terminal half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose

  5. Apparent Oral Clearance (CL/F)

    Drug clearance (CL) is a quantitative measure of the rate at which a drug substance is removed from the plasma. Clearance obtained after oral dose (apparent oral clearance \[CL/F\]) is influenced by the fraction of the dose absorbed (F).

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose

  6. Apparent Volume of Distribution (Vz/F)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose

  7. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Crizotinib Metabolite (PF-06260182)

    Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast) of Crizotinib metabolite (PF-06260182).

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose

  8. Area Under the Curve From Time Zero to Infinite Time [AUC (0 - ∞)] for Crizotinib Metabolite (PF-06260182)

    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞) of crizotinib metabolite (PF-06260182).

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose

  9. Maximum Observed Plasma Concentration (Cmax) for Crizotinib Metabolite (PF-06260182)

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose

  10. Time to Reach Maximum Observed Plasma Concentration (Tmax) for Crizotinib Metabolite (PF-06260182)

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose

  11. Metabolite to Parent Ratio of Maximum Observed Plasma Concentration (MRCmax)

    Metabolite (PF-06260182) to parent (crizotinib) molar ratio of maximum observed plasma concentration (MRCmax).

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose

  12. Metabolite to Parent Ratio of Area Under the Curve From Time Zero to Last Quantifiable Concentration (MRAUClast)

    Molar ratio of metabolite to parent area under the plasma concentration time-curve from time zero (pre-dose) to the last measured concentration (MRAUClast).

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose

  13. Metabolite to Parent Ratio of Area Under the Curve From Time Zero to Infinite Time [MRAUC (0- ∞)]

    Molar ratio of metabolite to parent area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0- ∞) \[MRAUC (0- ∞)\].

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose

07

Results

Posted Feb 8, 2012

Participant flow

First Intervention Period
Participant flow — First Intervention Period
MilestoneCrizotinib 250 mg FC First, Then Crizotinib 250 mg OLFCrizotinib 250 mg OLF First, Then Crizotinib 250 mg FC
Started1111
Completed1111
Not completed00
Washout Period (At Least 14 Days)
Participant flow — Washout Period (At Least 14 Days)
MilestoneCrizotinib 250 mg FC First, Then Crizotinib 250 mg OLFCrizotinib 250 mg OLF First, Then Crizotinib 250 mg FC
Started1111
Completed1111
Not completed00
Second Intervention Period
Participant flow — Second Intervention Period
MilestoneCrizotinib 250 mg FC First, Then Crizotinib 250 mg OLFCrizotinib 250 mg OLF First, Then Crizotinib 250 mg FC
Started1111
Completed1111
Not completed00

Outcome measures

PrimaryArea Under the Curve From Time Zero to Infinite Time [AUC (0 - ∞)]

AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hours (hrs) post crizotinib dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Infinite Time [AUC (0 - ∞)]
ng*hr/mLCrizotinib 250 mg FCCrizotinib 250 mg OLF
Area Under the Curve From Time Zero to Infinite Time [AUC (0 - ∞)]2833 ± 10992821 ± 1086
Statistical analysis
  • Crizotinib 250 mg FC vs Crizotinib 250 mg OLF · Ratio of adjusted means: 99.58 · 90% CI 91.08 to 108.87
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hrCrizotinib 250 mg FCCrizotinib 250 mg OLF
Time to Reach Maximum Observed Plasma Concentration (Tmax)5.00 (2.00 to 6.00)5.00 (2.00 to 6.00)
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).

Time frame:
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
ng*hr/mLCrizotinib 250 mg FCCrizotinib 250 mg OLF
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)2696 ± 10732679 ± 1069
Statistical analysis
  • Crizotinib 250 mg FC vs Crizotinib 250 mg OLF · Ratio of adjusted means: 99.35 · 90% CI 90.51 to 109.07
SecondaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLCrizotinib 250 mg FCCrizotinib 250 mg OLF
Maximum Observed Plasma Concentration (Cmax)121.0 ± 38.9117.2 ± 36.1
Statistical analysis
  • Crizotinib 250 mg FC vs Crizotinib 250 mg OLF · Ratio of adjusted means: 96.84 · 90% CI 88.22 to 106.32
SecondaryPlasma Terminal Half-Life (t1/2)

Plasma terminal half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Mean · hr
Plasma Terminal Half-Life (t1/2)
hrCrizotinib 250 mg FCCrizotinib 250 mg OLF
Plasma Terminal Half-Life (t1/2)35.58 ± 6.1236.35 ± 5.64
SecondaryApparent Oral Clearance (CL/F)

Drug clearance (CL) is a quantitative measure of the rate at which a drug substance is removed from the plasma. Clearance obtained after oral dose (apparent oral clearance \[CL/F\]) is influenced by the fraction of the dose absorbed (F).

Time frame:
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · Liter/hour (L/hr)
Apparent Oral Clearance (CL/F)
Liter/hour (L/hr)Crizotinib 250 mg FCCrizotinib 250 mg OLF
Apparent Oral Clearance (CL/F)88.21 ± 30.1788.61 ± 28.96
SecondaryApparent Volume of Distribution (Vz/F)

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution (Vz/F)
LiterCrizotinib 250 mg FCCrizotinib 250 mg OLF
Apparent Volume of Distribution (Vz/F)4473 ± 20894593 ± 2108
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Crizotinib Metabolite (PF-06260182)

Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast) of Crizotinib metabolite (PF-06260182).

Time frame:
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Crizotinib Metabolite (PF-06260182)
ng*hr/mLCrizotinib 250 mg FCCrizotinib 250 mg OLF
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Crizotinib Metabolite (PF-06260182)429.5 ± 242.3439.1 ± 271.5
SecondaryArea Under the Curve From Time Zero to Infinite Time [AUC (0 - ∞)] for Crizotinib Metabolite (PF-06260182)

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞) of crizotinib metabolite (PF-06260182).

Time frame:
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Infinite Time [AUC (0 - ∞)] for Crizotinib Metabolite (PF-06260182)
ng*hr/mLCrizotinib 250 mg FCCrizotinib 250 mg OLF
Area Under the Curve From Time Zero to Infinite Time [AUC (0 - ∞)] for Crizotinib Metabolite (PF-06260182)454.4 ± 242.1446.7 ± 273.1
SecondaryMaximum Observed Plasma Concentration (Cmax) for Crizotinib Metabolite (PF-06260182)
Time frame:
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Crizotinib Metabolite (PF-06260182)
ng/mLCrizotinib 250 mg FCCrizotinib 250 mg OLF
Maximum Observed Plasma Concentration (Cmax) for Crizotinib Metabolite (PF-06260182)30.98 ± 10.3932.56 ± 10.75
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) for Crizotinib Metabolite (PF-06260182)
Time frame:
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax) for Crizotinib Metabolite (PF-06260182)
hrCrizotinib 250 mg FCCrizotinib 250 mg OLF
Time to Reach Maximum Observed Plasma Concentration (Tmax) for Crizotinib Metabolite (PF-06260182)5.00 (4.00 to 6.00)5.00 (4.00 to 6.00)
SecondaryMetabolite to Parent Ratio of Maximum Observed Plasma Concentration (MRCmax)

Metabolite (PF-06260182) to parent (crizotinib) molar ratio of maximum observed plasma concentration (MRCmax).

Time frame:
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · Ratio
Metabolite to Parent Ratio of Maximum Observed Plasma Concentration (MRCmax)
RatioCrizotinib 250 mg FCCrizotinib 250 mg OLF
Metabolite to Parent Ratio of Maximum Observed Plasma Concentration (MRCmax)0.2482 ± 0.03490.2694 ± 0.0532
SecondaryMetabolite to Parent Ratio of Area Under the Curve From Time Zero to Last Quantifiable Concentration (MRAUClast)

Molar ratio of metabolite to parent area under the plasma concentration time-curve from time zero (pre-dose) to the last measured concentration (MRAUClast).

Time frame:
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · Ratio
Metabolite to Parent Ratio of Area Under the Curve From Time Zero to Last Quantifiable Concentration (MRAUClast)
RatioCrizotinib 250 mg FCCrizotinib 250 mg OLF
Metabolite to Parent Ratio of Area Under the Curve From Time Zero to Last Quantifiable Concentration (MRAUClast)0.1546 ± 0.02750.1589 ± 0.0274
SecondaryMetabolite to Parent Ratio of Area Under the Curve From Time Zero to Infinite Time [MRAUC (0- ∞)]

Molar ratio of metabolite to parent area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0- ∞) \[MRAUC (0- ∞)\].

Time frame:
0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96 and 144 hrs post crizotinib dose
Reported as:
Geometric mean · Ratio
Metabolite to Parent Ratio of Area Under the Curve From Time Zero to Infinite Time [MRAUC (0- ∞)]
RatioCrizotinib 250 mg FCCrizotinib 250 mg OLF
Metabolite to Parent Ratio of Area Under the Curve From Time Zero to Infinite Time [MRAUC (0- ∞)]0.1514 ± 0.02540.1535 ± 0.0259

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Crizotinib 250 mg FC—0/22 (0%)17/22 (77.3%)
Crizotinib 250 mg OLF—0/22 (0%)17/22 (77.3%)
Most frequent other events
Showing 10 of 25
Most frequent other events
EventCrizotinib 250 mg FCCrizotinib 250 mg OLF
DiarrhoeaGastrointestinal disorders9/2210/22
Abdominal painGastrointestinal disorders4/227/22
HeadacheNervous system disorders5/227/22
NauseaGastrointestinal disorders6/226/22
DyspepsiaGastrointestinal disorders0/222/22
EructationGastrointestinal disorders0/222/22
Gastrointestinal sounds abnormalGastrointestinal disorders2/221/22
DizzinessNervous system disorders2/220/22
Ear painEar and labyrinth disorders0/221/22
Abdominal distensionGastrointestinal disorders1/220/22

Baseline characteristics

Age Continuous
Age Continuous(years)Entire Study Population
Mean38.0 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female0
Male22
08

Study locations

1 site
  • Pfizer Investigational Site
    Bruxelles, B-1070, Belgium
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2011
First posted
Feb 17, 2011
Start
Mar 2011
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Results first posted
Feb 8, 2012
Last update
Feb 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01297595
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 17, 2011
Start date
Mar 2011
Primary completion
Apr 2011
Completion
Apr 2011
Results posted
Feb 8, 2012
Last update
Feb 16, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crizotinib

Start the discussion